Anti-fungal Drugs News
Drugs
> Anti-fungal DrugsAnti-fungal Drugs News is an EIN News Service for health professionals. Constantly updated news and information about health.
Latest Anti-fungal Drugs News
- Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 6 Nov 2009 08:36 GMT
... With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections Novexel, ... for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the ... novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This ...
- Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (AB 6 Nov 2009 08:48 GMT
... With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections Novexel, ... for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the ... novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This ...
- Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Stru 6 Nov 2009 09:53 GMT
... With Leading Oral Agent Linezolid for the Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections Novexel, ... for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the ... novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This ...
- Global OTC Pharmaceutical Market By Bharatbook.com 5 Nov 2009 09:03 GMT
... and allergy preparations • Dermatology - including antifungal agents and hair-loss treatments • Gastrointestinal drugs - including those for ... and creating opportunities for therapeutic areas and drug types in OTC pharma. Consumers are increasingly ...
- Fungal Nail Infections 5 Nov 2009 06:13 GMT
... nail and nailbed and may become painful. Treatment is only usually advised if: - Symptoms ... have severe problems with your immune system. Anti-fungal tablets may be prescribed, however the course ... may be removed along with treatment with antifungal medication. ...
- Natural remedies for psoriasis treat psoriasis with natural herbal treatment 4 Nov 2009 00:14 GMT
... for psoriasis treat psoriasis with natural herbal treatment Psoriasis, a chronic skin disease is now ... incorporation of over the counter or prescribed drugs. You can easily treat the onset once ... primrose. A concoction of these with the antifungal goodness of turmeric immediately aid in healing psoriasis. ...
- NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis 2 Nov 2009 22:36 GMT
... announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model ... fungus. What is remarkable is that, after treatment, the Aganocide formulations were able to eradicate ... be highly effective against bacteria, including its multi-drug resistant strains (such as MRSA), viruses and ...
- Novobiotics - Positive Initial Phase IIa Data 2 Nov 2009 14:35 GMT
... the design and development of novel peptide antifungal and antibacterial therapeutics, confirms that the first patients ... enrolled in its Novexatin® Phase IIa clinical trial have successfully completed a 28 day daily ... antifungal compound. Novexatin® (NP213), a topical (brush-on) treatment for fungal nail infection, is NovaBiotics’ lead ...
- Nature cure for psoriasis natural remedies for psoriasis 4 Nov 2009 00:13 GMT
... incorporation of over the counter or prescribed drugs. You can easily treat the onset once ... nice hot bathing is unparalleled in the treatment for Psoriasis. If you double the effect ... primrose. A concoction of these with the antifungal goodness of turmeric immediately aid in healing psoriasis. ...
- BioDelivery Sciences posts $2.6 million loss for the quarter 6 Nov 2009 15:51 GMT
... FDA approval for its Onsolis cancer pain treatment for people aged 18 and older who ... from the to study whether BDSI’s oral drug delivery technology can be used with antifungal medications. “As a result of the foregoing, the ...
- MethylGene Reports Third Quarter 2009 Financial Results 5 Nov 2009 12:56 GMT
... quarter include: - The U.S. Food and Drug Administration lifted the partial clinical hold for new ... Trial 102 (intermittent schedule). - MGCD290, MethylGene's antifungal compound, demonstrated favorable results in three Phase ... its funded research collaboration with MethylGene, initially formed in March 28, 2008, for an additional ...
- Resistant Bacteria Bring New Challenges to Anti-Infectives Market 2 Nov 2009 16:30 GMT
... World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance ... report focuses on three key segments of treatment: -- Antifungals (Allylamines, Azoles,Polyene Macrolides and Other ... of Leading Providers -- Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and ...
- Resistant Bacteria Bring New Challenges to Anti-Infectives Market 2 Nov 2009 16:35 GMT
... World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance ... report focuses on three key segments of treatment: -- Antifungals (Allylamines, Azoles,Polyene Macrolides and Other ... of Leading Providers -- Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and ...
- MethylGene Reports Third Quarter 2009 Financial Results 5 Nov 2009 13:47 GMT
... 30, 2009. - The U.S. Food and Drug Administration lifted the partial clinical hold for new ... Trial 102 (intermittent schedule). - MGCD290, MethylGene's antifungal compound, demonstrated favorable results in three Phase ... its funded research collaboration with MethylGene, initially formed in March 28, 2008, for an additional ...
- MethylGene Reports Third Quarter 2009 Financial Results (MRW) 5 Nov 2009 12:59 GMT
... in Boston for Trial 102 (intermittent schedule). antifungal compound, demonstrated favorable results in three Phase ... expected to commence by year-end. , initially formed in March 28, 2008, for an additional ... scale-up and optimization efforts for MGCD265 clinical drug supply. General and administrative expenses in the third ...
Powered by 
These stories are not published by IPD Group, Inc. and these links will take you to other websites. Some of these websites require their own registration to read their stories.
<<< Please read the disclaimer for more details.>>> | |
Healthcare Industry Today
|
a digital news provider
bbc.co.uk:
healthday.com:
reuters.com: